» Articles » PMID: 17983809

Hepatitis C Virus Triggers Apoptosis of a Newly Developed Hepatoma Cell Line Through Antiviral Defense System

Overview
Specialty Gastroenterology
Date 2007 Nov 7
PMID 17983809
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Hepatitis C virus (HCV) has a tendency to cause chronic viral infection. Viral evasion of host immune systems plays a key role in the pathogenesis of HCV. However, the interaction between HCV and hepatocyte innate antiviral defense systems is not understood. The aim of this study was to examine how human hepatocytes respond to HCV infection.

Methods: We have established a novel human hepatoma cell line, LH86, from a well-differentiated hepatocellular carcinoma tissue. An infectious HCV isolate, JFH-1, was used to infect LH86 cells. HCV replication and apoptosis after viral infection were examined. Mechanisms of HCV-induced apoptosis were determined. Type I interferon induction and the relevant signaling molecules were examined.

Results: LH86 cells permitted JFH-1 HCV infection. The viral infection caused massive apoptosis. The apoptosis was related to viral replication, because blocking viral entry with anti-CD81 or suppressing viral replication with interferon protected cells from HCV-induced apoptosis. The HCV-induced apoptosis appeared to be triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors, death receptor 4 and death receptor 5, which were up-regulated in HCV infection. HCV also activated interferon response factor 3, which induced expression of interferon and TRAIL in LH86 cells.

Conclusions: Our study showed that a specific HCV isolate, JFH-1, is cytopathic in this new hepatoma cell line. LH86 cells mount an intact innate antiviral defense through induction of interferon and triggering apoptosis of infected cells. This study reveals a novel mechanism by which host hepatocytes respond to acute HCV infection.

Citing Articles

Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma.

Yang L, Pham K, Xi Y, Wu Q, Liu D, Robertson K PLoS One. 2025; 20(1):e0317401.

PMID: 39841705 PMC: 11753693. DOI: 10.1371/journal.pone.0317401.


Crosstalk Between Pyroptosis and Apoptosis in Hepatitis C Virus-induced Cell Death.

Wallace H, Wang L, Gardner C, Corkum C, Grant M, Hirasawa K Front Immunol. 2022; 13:788138.

PMID: 35237259 PMC: 8882739. DOI: 10.3389/fimmu.2022.788138.


The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.

Deng R, Zuo C, Li Y, Xue B, Xun Z, Guo Y Cell Mol Immunol. 2020; 17(11):1163-1179.

PMID: 32963356 PMC: 7784998. DOI: 10.1038/s41423-020-00549-9.


Hepatitis C Virus: Evading the Intracellular Innate Immunity.

Ferreira A, Ramos B, Nunes A, Ribeiro D J Clin Med. 2020; 9(3).

PMID: 32183176 PMC: 7141330. DOI: 10.3390/jcm9030790.


Engineered Livers for Infectious Diseases.

Gural N, Mancio-Silva L, He J, Bhatia S Cell Mol Gastroenterol Hepatol. 2018; 5(2):131-144.

PMID: 29322086 PMC: 5756057. DOI: 10.1016/j.jcmgh.2017.11.005.